Functional and isokinetic assessment of muscle strength in patients with idiopathic inflammatory myopathies

References

• Plotz PH, Rider LG, Targoff IN, Raben N, O'Hanlon TP, Miller FW, Conference NIH. Myositis: Immunologic contributions to understanding its cause, pathogenesis, and therapy. Ann Intern Med 1995; 122(9)715–724
   PubMedGoogle Scholar
• Miller FW. Classification and prognosis of inflammatory muscle disease. Rheum Dis Clin North Am 1994; 20(4)811–823
   PubMedGoogle Scholar
• Targoff IN, Miller FW, Medsger TA, Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997; 9: 527–535
   PubMedGoogle Scholar
• Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362: 971–982
   PubMed Web of Science ®Google Scholar
• Studynková JT, Kuchen S, Jeisy E, Schedel J, Charvát F, Jarosová K, et al. The expression of cyclooxygenase-1, cyclooxygenase-2 and 5-lipoxygenase in inflammatory muscle tissue of patients with polymyositis and dermatomyositis. Clin Exp Rheumatol 2004; 22: 395–402
   PubMed Web of Science ®Google Scholar
• Zampieri S, Ghirardello A, Iaccarino L, Tarricone E, Gambari PF, Doria A. Anti-JO-1 antibodies. Autoimmunity 2005; 38: 73–78
   PubMed Web of Science ®Google Scholar
• Vered M, Yehuda S. Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 2005; 38: 235–245
   PubMedGoogle Scholar
• Ponyi A, Borgulya G, Constantin T, Vancsa A, Gergely L, Danko K. Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis. Rheumatology 2005; 44: 83–88
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Feldman BM. Clinical outcomes in juvenile dermatomyositis. Curr Opin Rheumatol 2002; 14: 658–662
   PubMedGoogle Scholar
• Ruperto N, Ravelli A, Murray KJ, Lovell DJ, Andersson-Gare B, Feldmnn BM, et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology 2003; 42: 1452–1459
   PubMedGoogle Scholar
• Ponyi A, Constantin T, Balogh Z, Szalai Z, Borgulya G, Molnar K, et al. Disease course, frequency of relapses and survival of 73 patients with juvenile or adult dermatomyositis. Clin Exp Rheumatol 2005; 23: 50–56
   PubMedGoogle Scholar
• Moxley RT. Evaluation of neuromuscular function in inflammatory myopathy. Rheum Dis Clin North Am 1994; 20(4)827–843
   PubMedGoogle Scholar
• Drouet B, Le Loet X, Vittecoq O, Nuovet G, Lauret P, Tron P, et al. A study of long-term survival, functional outcome and quality of life in patients with polymyositis and dermatomyositis. Rev Rhum Engl Ed 1996; 63: 321–330
   PubMedGoogle Scholar
• Fafalak RG, Peterson MGE, Kagen LJ. Strength in polymyositis and dermatomyositis: Best outcome in patients treated early. J Rheumatol 1994; 21: 643–648
   PubMed Web of Science ®Google Scholar
• Badrising UA, Maat-Schieman MLC, Ferrari MD, Zwinderman AH, Wessels JAM, Breedveld FC, et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002; 51: 369–372
   PubMed Web of Science ®Google Scholar
• Nzeusseu A, Brion F, Lefebvre C, Knoops P, Devogelaer JP, Houssiau FA. Functional outcome of myositis patients: Can a low-dose glucocorticoid regimen achieve good functional results?. Clin Exp Rheumatol 1999; 17: 441–446
   PubMed Web of Science ®Google Scholar
• Maugars YM, Berthelot JM, Abbas AA, Mussini JM, Nguyen JM, Prost AM. Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol 1996; 14: 263–274
   PubMed Web of Science ®Google Scholar
• Rider LG, Giannini EH, Brunner EI, Ruperto N, James-Newton L, Reed AM, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004; 50: 2281–2290
   PubMed Web of Science ®Google Scholar
• Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD, et al. Validation and clinical significance of the childhood myositis assessment scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004; 50: 1595–1603
   PubMed Web of Science ®Google Scholar
• Gaines JM, Talbot LA. Isokinetic strength testing in research and practice. Biol Res Nurs 1999; 1: 57–64
   PubMedGoogle Scholar
• Wiesenger GF, Quittan M, Aringer M, Seeber A, Volc-Platzer B, Smolen J, et al. Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme. Br J Rheumatol 1998; 37: 196–200
   PubMedGoogle Scholar
• Wiesenger GF, Quittan M, Nhur M, Volc-Platzer B, Ebenbichler G, Zehetgruber M, et al. Aerobic capacity in adult dermatomyositis/polymyositis patients and healthy controls. Arch Phys Med Rehabil 2000; 81: 1–5
   PubMedGoogle Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975; 292: 344–347
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975; 292: 403–407
   PubMed Web of Science ®Google Scholar
• Neri R, Mosca M, Grazzini T, Tavoni A, Pasero G, Bombardieri S. Outcome funzionale a lungo termine delle miopatie infiammatorie idiopatiche. Long term functional outcome of idiopathic inflammatory myopathies. Reumatismo 2001; 53: 40–45
   PubMedGoogle Scholar
• Henriksson KG, Sandstedt P. Polymyositis treatment and prognosis. A study of 107 patients. Acta Neurol Scand 1982; 65: 280–300
   PubMed Web of Science ®Google Scholar
• Kannus P. Isokinetic evaluation of muscular performance: Implications for muscle testing and rehabilitation. Int J Sports Med 1994; 15 S 1: S11–S18
   Google Scholar
• Stoll T, Bruhlmann P, Stucki G, Seifert B, Michel BA. Muscle strength assessment in polymyositis and dermatomyositis: Evaluation of the reliability and clinical use of a new, quantitative, easily applicable method. J Rheumatol 1995; 22: 473–477
   PubMed Web of Science ®Google Scholar
• Jepsen J, Laursen L, Larsen A, Hagert CG. Manual strength testing in 14 upper limb muscles: A study of inter-rater reliability. Acta Orthop Scand 2004; 75: 442–448
   PubMed Web of Science ®Google Scholar
• Sultan SM. The assessment and importance of disease activity versus disease damage in patients with inflammatory myopathy. Curr Rheumatol Rep 2003; 5: 445–450
   PubMedGoogle Scholar
• Kannus P. Normality, variability and predictability of work, power and torque acceleration energy with respect to peak torque in isokinetic muscle testing. Int J Sports Med 1992; 13: 249–256
   PubMedGoogle Scholar
• Oddis CV. Therapy of inflammatory myopathy. Rheum Dis Clin North Am 1994; 20(4)899–917
   PubMedGoogle Scholar